YOEL ROMERO VS. GOLD STAR DISTRIBUTION (L-7287-17, MIDDLESEX COUNTY AND STATEWIDE)

New Jersey Superior Court Appellate Division·Decided June 24, 2021·No. A-0379-20·Published

Opinion

NOT FOR PUBLICATION WITHOUT THE APPROVAL OF THE APPELLATE DIVISION

SUPERIOR COURT OF NEW JERSEY APPELLATE DIVISION

DOCKET NO. A-0379-20

YOEL ROMERO,

Plaintiff-Respondent, APPROVED FOR PUBLICATION

v. June 24, 2021

APPELLATE DIVISION

GOLD STAR DISTRIBUTION, LLC, d/b/a GOLDSTAR PERFORMANCE PRODUCTS, a business entity,

Defendant-Appellant.

Argued April 28, 2021 – Decided June 24, 2021 Before Judges Whipple, Rose and Firko.

On appeal from the Superior Court of New Jersey, Law Division, Middlesex County, Docket No. L-7287-

17.

Desiree L. Wilfong argued the cause for appellant (Lucas & Cavalier, LLC, attorneys; Desiree L.

Wilfong and Robert M. Cavalier, of counsel and on the briefs).

Jeffrey S. Craig and Howard Jacobs (Law Offices of Howard Jacobs) of the California bar, admitted pro hac vice, argued the cause for respondent (Craig, Annin & Baxter, LLP, attorneys; Jeffrey S. Craig and Howard Jacobs on the briefs).

The opinion of the court was delivered by FIRKO, J.A.D.

Defendant Gold Star Distribution, LLC, d/b/a Goldstar Performance Products, appeals from an August 25, 2020 Law Division order denying its motion to vacate final judgment by default. In this opinion, we reiterate well- settled principles set forth in Rule 4:50-1 and the standard for calculating damages under the New Jersey Consumer Fraud Act (CFA), N.J.S.A. 56:8-1 to -226. We affirm in part, and reverse and remand in part, on the issue of damages.

I.

The following facts are derived from the record on appeal. Plaintiff, a resident of Miami, Florida, is a professional mixed martial arts (MMA) athlete who competed in the Ultimate Fighting Championship (UFC), the highest level of competition in MMA. He is also a former world champion freestyle wrestler who earned a silver medal at the 2000 Olympic Games.

Defendant is a dietary supplement company, doing business as Goldstar Performance Products, having a principal place of business in New Jersey. The president of Gold Star Distribution, LLC is Steven Hankin. According to plaintiff, he consumed one of defendant's products called "SHED RX," relying upon defendant's representation that the product it manufactured, marketed, A-0379-20

and sold, was free of any substances banned by the World Anti-Doping Agency (WADA). SHED RX is marketed as a fast-acting, maximum strength diuretic water weight loss muscle definition formula and is sold in capsule form. The SHED RX label states it "uses natural ingredients" and that defendant adheres to "strict GC/MS and HPLC testing procedures." 1 In order to ensure compliance with WADA regulations, plaintiff conducted his own research to confirm SHED RX did not contain any banned substances, including ibutamoren, 2 in order to avoid being disqualified from competitions. Plaintiff also read the SHED RX label and discussed ingesting the product with his colleagues to ensure its compliance with WADA's

1 GC/MS stands for gas chromatography coupled with mass spectrometry. "The most sophisticated drug-testing approach is gas chromatography coupled with mass spectrometry (GC/MS), which is regarded as a 'gold standard'; it is used in confirmatory testing." B.M. Kapur, Drug Testing Methods and Clinical Interpretations of Test Results, 45 Bull. Narcotics 115 (1993).

HPLC stands for high performance liquid chromatography. "[HPLC] is now one of the most powerful tools in analytical chemistry as it has the ability to identify, separate and quantitate the compounds that are present in any sample that can be dissolved in any liquid." Vikram Kamar et al., An Overview on HPLC Method Development, Optimization and Validation Process for Drug Analysis, 2 Pharm. & Chem. J. 30, 31 (2015). 2 Ibutamoren, also known as ibutamoren mesylate and MK-0677, is a growth hormone supplement that is consumed orally and is not currently approved by the Food and Drug Administration. Ibutamoren is available by prescription through compounding pharmacies in the United States and abroad. John T. Sigalos & Alexander W. Pastuszak, The Safety and Efficacy of Growth Hormone Secretagogues, 6(1) Sexual Med. Rev. 45 (2018).

A-0379-20

regulations. Being satisfied SHED RX was safe and not contraindicated by WADA, plaintiff started taking the product. To his surprise, when a random urine sample required by the United States Anti-Doping Agency (USADA) was collected on December 16, 2015, plaintiff tested positive for ibutamoren. The urine sample was tested by the Sports Medicine Research and Testing Laboratory (SMRTL) in Salt Lake City, Utah, which is accredited by WADA.

This was the first time plaintiff ever tested positive for a banned substance in his athletic career. Because of his positive test result, plaintiff was suspended by the UFC for a period of six months, commencing on January 12, 2016. According to plaintiff, he was a "lead contender" for the UFC middleweight title at the time and was denied the opportunity to fight. Plaintiff also claims he was denied other promising career opportunities and was characterized as a "doper" by the press and the public.

The USADA was provided with a capsule from the bottle of SHED RX used by plaintiff and sent it to SMRTL for testing. Several capsules from an independently purchased SHED RX bottle were also tested by SMRTL and contained ibutamoren—twelve micrograms per capsule. Ibutamoren was not listed as an ingredient on the SHED RX label for the bottles examined, which were sold throughout stores in the United States and online.

A-0379-20

On December 11, 2017, plaintiff filed a complaint in the Law Division against defendant alleging negligence (count one), products liability (count two), breach of implied warranties (count three), intentional misrepresentation (count four), negligent misrepresentation (count five), violations of the CFA (count six), and punitive damages (count seven). Specifically, plaintiff alleged defendant failed to exercise ordinary care by carelessly and negligently maintaining the production facility where SHED RX was contaminated with ibutamoren; negligently sold SHED RX to competitive athletes and the general public; failed to design a safe manufacturing process to eliminate cross - contamination with other products; failed to adhere to government regulations; and failed to disclose known dangers inherent in the consumption of SHED RX.

Goldstar Performance Products was named as defendant in the caption based on the packaging and advertising materials of the SHED RX product , as well as the LinkedIn profile of Hankin and the email address he actively used, shankin@goldstarperformanceproducts.com. Goldstar Performance Products is the trade name for Gold Star Distribution, LLC and the entity that SHED RX was marketed under.

On December 12, 2017, a summons was issued to defendant, and plaintiff's counsel enlisted a private process server to serve the summons and A-0379-20

complaint on defendant. Because defendant and its president, Hankin, evaded service of process, service was not achieved, and the matter was scheduled on the court's administrative dismissal list. On June 6, 2018, plaintiff filed a motion to remove the complaint from the administrative dismissal list and to allow substituted service of the summons and complaint upon defendant by mail pursuant to Rule 4:4-5(a)(2) or by publication pursuant to Rule 4:4- 5(a)(3).

Free access — add to your briefcase to read the full text and ask questions with AI

YOEL ROMERO VS. GOLD STAR DISTRIBUTION (L-7287-17, MIDDLESEX COUNTY AND STATEWIDE), (N.J. Ct. App. 2021).

YOEL ROMERO VS. GOLD STAR DISTRIBUTION (L-7287-17, MIDDLESEX COUNTY AND STATEWIDE) (YOEL ROMERO VS. GOLD STAR DISTRIBUTION (L-7287-17, MIDDLESEX COUNTY AND STATEWIDE)) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
Armstrong v. Manzo
380 U.S. 545 (Supreme Court, 1965)
Anthony D'agostino v. Ricardo Maldonado (068940)
78 A.3d 527 (Supreme Court of New Jersey, 2013)
Heinl v. Heinl
671 A.2d 147 (New Jersey Superior Court App Division, 1996)
Jameson v. Great Atlantic & Pac. Tea Co.
833 A.2d 626 (New Jersey Superior Court App Division, 2003)
Deg, LLC v. Township of Fairfield
966 A.2d 1036 (Supreme Court of New Jersey, 2009)
Bosland v. Warnock Dodge, Inc.
964 A.2d 741 (Supreme Court of New Jersey, 2009)
Davis v. DND/Fidoreo, Inc.
721 A.2d 312 (New Jersey Superior Court App Division, 1998)
Lemelledo v. Beneficial Management Corp. of America
696 A.2d 546 (Supreme Court of New Jersey, 1997)
Parks v. Colonial Penn Insurance
484 A.2d 4 (Supreme Court of New Jersey, 1984)
Thiedemann v. Mercedes-Benz USA, LLC
872 A.2d 783 (Supreme Court of New Jersey, 2005)
Goldhaber v. Kohlenberg
928 A.2d 948 (New Jersey Superior Court App Division, 2007)
Heimbach v. Mueller
550 A.2d 993 (New Jersey Superior Court App Division, 1988)
Curtis v. Finneran
417 A.2d 15 (Supreme Court of New Jersey, 1980)
PROF'L STONE APPLICATORS v. Carter
975 A.2d 1039 (New Jersey Superior Court App Division, 2009)
Liberty Mutual Insurance v. Land
892 A.2d 1240 (Supreme Court of New Jersey, 2006)
Sobel v. Long Island Entertainment
747 A.2d 796 (New Jersey Superior Court App Division, 2000)
Cole v. Laughrey Funeral Home
869 A.2d 457 (New Jersey Superior Court App Division, 2005)
Cox v. Sears Roebuck & Co.
647 A.2d 454 (Supreme Court of New Jersey, 1994)